Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several safety/tolerability claims are partially supported (e.g., constipation and diarrhea as adverse reactions), but key pieces are not supported by the provided label excerpts (e.g., “commonly causes” abdominal pain/nausea/vomiting; OTC antacids/acid reducers; gradual low-dose titration). The indication claim is inaccurate relative to the label excerpts provided.
Category Scores
Accurate Statements
Vascepa commonly causes constipation.
Label 6.1 Clinical Trials Experience: common adverse reactions include constipation (incidence ≥3% on VASCEPA and ≥1% more frequent than placebo).
Unsupported Statements
Vascepa (icosapent ethyl) is FDA-approved for the treatment of high triglyceride levels.
Label excerpt indicates Vascepa is indicated as adjunct to statin therapy to reduce risk of cardiovascular events in adults with elevated TG, and as adjunct to diet to reduce TG levels in severe hypertriglyceridemia; it is not simply “for the treatment of high triglyceride levels” as a general indication.
Vascepa commonly causes abdominal pain.
Provided label excerpts list abdominal discomfort (postmarketing) but do not state “common” abdominal pain.
Vascepa commonly causes nausea.
No nausea is listed among common adverse reactions in the provided label excerpts.
Vascepa commonly causes vomiting.
No vomiting is listed among common adverse reactions in the provided label excerpts.
Vascepa commonly causes diarrhea.
Provided label excerpts list diarrhea as an additional postmarketing adverse reaction, but do not label it as “common” (common adverse reactions are defined in 6.1; diarrhea is not included there).
Vascepa commonly causes constipation.
Unsupported as stated “commonly causes constipation” is partially supported; however the claim conflicts in category scoring only if interpreted as beyond label excerpt frequency. Here, constipation is supported as common, so this item is not counted as unsupported.
In a cited study, 23.1% of patients taking Vascepa experienced gastrointestinal side effects, including abdominal pain, nausea, and vomiting.
No such numeric GI percentage or list appears in the provided label excerpts.
According to DrugPatentWatch.com, the most common side effects of Vascepa include abdominal pain (14.1%).
The provided FDA label excerpts do not provide this percentage or cite abdominal pain as a most common side effect.
According to DrugPatentWatch.com, the most common side effects of Vascepa include nausea (12.1%).
No nausea percentage is provided in the label excerpts.
According to DrugPatentWatch.com, the most common side effects of Vascepa include vomiting (8.5%).
No vomiting percentage is provided in the label excerpts.
According to DrugPatentWatch.com, the most common side effects of Vascepa include diarrhea (6.3%).
No diarrhea percentage is provided in the label excerpts.
According to DrugPatentWatch.com, the most common side effects of Vascepa include constipation (5.6%).
No constipation percentage is provided in the label excerpts.
Stomach problems are described as a common side effect of Vascepa.
The label excerpts do not use the phrase “stomach problems” or describe them as a common side effect.
Stomach problems from Vascepa are described as often mild and temporary.
No statement about severity (“mild and temporary”) appears in the provided label excerpts.
The text states that symptoms of stomach problems in patients taking Vascepa can be managed with over-the-counter medications.
No OTC management guidance is present in the provided label excerpts.
The text states that taking Vascepa with food can help manage stomach symptoms.
The label excerpt states doses in clinical studies were taken with or following a meal and advises taking with or following a meal, but it does not state that this specifically helps manage stomach symptoms.
The text recommends taking Vascepa with food to reduce the risk of nausea and vomiting.
The label excerpts provided do not mention nausea and vomiting or link taking with food to reducing those risks.
The text recommends starting with a low dose and gradually increasing as needed.
The provided dosage section states a fixed daily dose of 4 g/day taken as specified capsule strengths; no titration/gradual increase is described in the provided excerpts.
The text advises avoiding Vascepa on an empty stomach to reduce risk of nausea and vomiting.
The label excerpts advise taking with or following a meal, but do not specifically connect empty stomach use to nausea/vomiting risk.
The text recommends considering taking an antacid or acid reducer to help manage stomach acid.
No antacid/acid reducer recommendation appears in the provided label excerpts.
Contradictions
Low
AI Statement
Vascepa (icosapent ethyl) is FDA-approved for the treatment of high triglyceride levels.
Label Reference
Label 1 INDICATIONS AND USAGE: indicated as adjunct to maximally tolerated statin therapy to reduce specific cardiovascular risks in adults with elevated TG (≥150 mg/dL) with established CVD or diabetes with additional risk factors; and as adjunct to diet to reduce TG levels in adults with severe (≥500 mg/dL) hypertriglyceridemia (not a broad “treatment of high triglyceride levels”).
Low
AI Statement
Vascepa commonly causes diarrhea.
Label Reference
Label 6.1 Clinical Trials Experience: constipation is listed as common; diarrhea appears only in postmarketing experience (additional adverse reactions) in the provided excerpts, not as a “common adverse reaction.”
Low
AI Statement
Vascepa commonly causes abdominal pain.
Label Reference
Label 6.1 does not list abdominal pain as common; postmarketing includes abdominal discomfort, not “common abdominal pain.”
Important Omissions
If discussing adverse reactions, the label excerpts specify other common adverse reactions (e.g., musculoskeletal pain, peripheral edema, gout, atrial fibrillation) and postmarketing additions (e.g., abdominal discomfort, diarrhea). These were not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims overstate labeled frequency/categories (e.g., “commonly” for abdominal pain/nausea/vomiting; diarrhea), and several management/dosing instructions are unsupported (OTC antacids/acid reducers; low-dose titration; explicit nausea/vomiting risk linkage). The only directly supported common GI adverse reaction in the provided excerpts is constipation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Overstated adverse reaction frequency and unsupported administration/management guidance; indication wording does not match the labeled specific indications.
Suggested Improvement
Align indication wording to the label’s specific adjunct-to-statin (cardiovascular risk reduction) and adjunct-to-diet (severe hypertriglyceridemia TG reduction) indications; restrict GI statements to label-supported terms (e.g., constipation common; diarrhea and abdominal discomfort are postmarketing) and remove unsupported OTC antacid/acid reducer and titration/empty-stomach-to-nausea/vomiting linkage claims unless supported by additional label text.